HTWR Profile
HeartWare International, Inc. (HTWR) was a medical technology company that focused on the development and commercialization of implantable heart pumps. The company was headquartered in Framingham, Massachusetts, and was founded in 2000.
HeartWare International's flagship product was the HVAD System, which was a ventricular assist device that was used to support patients with advanced heart failure. The device was implanted in the patient's chest and was designed to supplement the pumping function of the heart. The HVAD System was approved for use in the United States by the Food and Drug Administration (FDA) in 2012.
However, in 2016, HeartWare International was acquired by Medtronic, a global medical technology company, for approximately $1.1 billion. Medtronic has since incorporated HeartWare International's product portfolio into its broader portfolio of medical devices.
Investors in HeartWare International should be aware of the risks associated with investing in medical technology companies, which are subject to a range of regulatory, clinical, and commercial risks. The development and commercialization of medical devices can be a long and expensive process, and companies in this industry often face challenges in obtaining regulatory approval, establishing reimbursement, and achieving widespread adoption of their products.
In conclusion, HeartWare International was a medical technology company that focused on the development and commercialization of implantable heart pumps. The company's flagship product, the HVAD System, was approved for use in the United States in 2012. HeartWare International was acquired by Medtronic in 2016, and the company's product portfolio has since been incorporated into Medtronic's broader portfolio of medical devices. Investors in medical technology companies should be aware of the regulatory, clinical, and commercial risks associated with investing in this industry.
|
